메뉴 건너뛰기




Volumn 33, Issue 9, 2009, Pages

CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERFERON;

EID: 67549094666     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.024     Document Type: Letter
Times cited : (6)

References (7)
  • 1
    • 4644341516 scopus 로고    scopus 로고
    • Discontinuation of imatinib therapy after achieving a molecular response
    • Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
    • (2004) Blood , vol.104 , pp. 2204-2205
    • Cortes, J.1    O'Brien, S.2    Kantarjian, H.3
  • 2
    • 1342343034 scopus 로고    scopus 로고
    • Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
    • Mauro M.J., Druker B.J., and Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leukemia Res 28 Suppl 1 (2004) S71-S73
    • (2004) Leukemia Res , vol.28 , Issue.SUPPL. 1
    • Mauro, M.J.1    Druker, B.J.2    Maziarz, R.T.3
  • 3
    • 10644257701 scopus 로고    scopus 로고
    • CML cytogenetic relapse after cessation of imatinib therapy
    • Usuki K., Iijima K., Iki S., and Urabe A. CML cytogenetic relapse after cessation of imatinib therapy. Leukemia Res 29 (2005) 237-238
    • (2005) Leukemia Res , vol.29 , pp. 237-238
    • Usuki, K.1    Iijima, K.2    Iki, S.3    Urabe, A.4
  • 4
    • 33846023983 scopus 로고    scopus 로고
    • Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    • Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
    • (2007) Blood , vol.109 , pp. 58-60
    • Rousselot, P.1    Huguet, F.2    Rea, D.3    Legros, L.4    Cayuela, J.M.5    Maarek, O.6
  • 5
    • 18144451171 scopus 로고    scopus 로고
    • Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders
    • Bonifazi F., de Vivo A., Rosti G., Guilhot F., Guilhot J., Trabacchi E., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 10 (2001) 3074-3081
    • (2001) Blood , vol.98 , Issue.10 , pp. 3074-3081
    • Bonifazi, F.1    de Vivo, A.2    Rosti, G.3    Guilhot, F.4    Guilhot, J.5    Trabacchi, E.6
  • 6
    • 0036137923 scopus 로고    scopus 로고
    • Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa
    • Mahon F.X., Delbrel X., Cony-Makhoul P., Fabères C., Boiron J.M., Barthe C., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20 (2002) 214-220
    • (2002) J Clin Oncol , vol.20 , pp. 214-220
    • Mahon, F.X.1    Delbrel, X.2    Cony-Makhoul, P.3    Fabères, C.4    Boiron, J.M.5    Barthe, C.6
  • 7
    • 43749083706 scopus 로고    scopus 로고
    • Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation
    • Carella A.M. Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation. Leukemia 22 (2008) 1090-1091
    • (2008) Leukemia , vol.22 , pp. 1090-1091
    • Carella, A.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.